Search hospitals

>

Washington

>

Renton

Valley Medical Center

Claim this profile

Renton, Washington 98055

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

161 reported clinical trials

4 medical researchers

Photo of Valley Medical Center in RentonPhoto of Valley Medical Center in Renton

Summary

Valley Medical Center is a medical facility located in Renton, Washington. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Valley Medical Center is involved with conducting 161 clinical trials across 345 conditions. There are 4 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, John A. Keech, and Richard Wall, MD.

Area of expertise

1

Lung Cancer

Global Leader

Valley Medical Center has run 35 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

Valley Medical Center has run 32 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Valley Medical Center

Lung Cancer

Breast Cancer

Bladder Cancer

Breast cancer

Cancer

Ovarian Cancer

Esophageal cancer

Colorectal Cancer

Kidney Cancer

Pancreatic Cancer

Image of trial facility.

Telisotuzumab Vedotin vs. Docetaxel

for Non-Small Cell Lung Cancer

This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Valley Medical Center?